Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Idiopathic Pulmonary Fibrosis Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

101 recruiting trials for Idiopathic Pulmonary Fibrosis. Eligibility criteria explained in plain English.

TrialFinderData lists 101 Idiopathic Pulmonary Fibrosis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 43% (17 studies); the largest phase groups are Phase 2: 17, Phase 1: 12, Phase 3: 3, Early Phase 1: 3.

Research is led by Children's Hospital Medical Center, Cincinnati (4), University of Kansas Medical Center (3), Hospices Civils de Lyon (3), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (drug, 16 trials), followed by Blood draw, HRS-9813.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
101
Total Trials
101
Recruiting Now
3
Phase 3 Trials
10
Sponsors

Track Idiopathic Pulmonary Fibrosis trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06528418

Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model...

Sponsor: ChromX HealthEnrolling: 100001 location
RECRUITINGPhase 1 / Phase 2NCT07464132

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases

The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related...

Sponsor: Peking Union Medical College HospitalEnrolling: 301 location
RECRUITINGNCT00001532

Role of Genetic Factors in the Development of Lung Disease

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung...

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)Enrolling: 35002 locations
RECRUITINGNCT06539169

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in...

Sponsor: xCuresEnrolling: 10001 location
RECRUITINGPhase 1NCT06589219

Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

The purpose of this study is to assess the safety, tolerability and pharmacokinetics single and multiple inhaled doses of CMR316 in healthy volunteers and patients with Idiopathic...

Sponsor: Calibr, a division of Scripps ResearchEnrolling: 1061 location
RECRUITINGPhase 3NCT07201922

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of...

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred,...

Sponsor: Boehringer IngelheimEnrolling: 8020 locations
RECRUITINGNCT06815185

Rehabilitation Counselling for Patients with Interstitial Lung Disease

Idiopathic pulmonary fibrosis (IPF) is a rare chronic progressive disease of unknown etiology that affects physical and emotional well-being. It is characterized by irreversible...

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaEnrolling: 401 location
RECRUITINGPhase 1NCT05121779

Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT

68Ga-fibroblast activating protein inhibitors(FAPI) has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated...

Sponsor: Peking Union Medical College HospitalEnrolling: 801 location
RECRUITINGPhase 2NCT06189820

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.

Sponsor: Erasme University HospitalEnrolling: 701 location
RECRUITINGNCT07541638

Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases

Connective tissue diseases (CTDs) cover a broad range of systemic rheumatic disorders characterized by abnormal immune activation, chronic inflammatory response, and fibrosis of...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 2001 location
RECRUITINGPhase 1NCT06821464

A Trial of HRS-9813 in Healthy Subjects

The study is being conducted to evaluate the safety and pharmacokinetics of HRS-9813 after multiple oral administration in healthy subjects.

Sponsor: Guangdong Hengrui Pharmaceutical Co., LtdEnrolling: 601 location
RECRUITINGPhase 2NCT03803787

Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients

This randomized clinical study aims to assess whether prophylactic treatment with inhaled steroids in patients with locally advanced or concomitantly treated non-small cell lung...

Sponsor: Instituto Nacional de Cancerologia de MexicoEnrolling: 722 locations
RECRUITINGPhase 2NCT04530383

Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

The purpose of this study is to assess the efficacy of metformin to improve airway ion channel function in those with CF-related diabetes (CFRD)

Sponsor: University of Kansas Medical CenterEnrolling: 301 location
RECRUITINGNCT06457451

Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With...

Cystic fibrosis is an autosomal recessive inherited disease linked to various mutations in the gene coding for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)...

Sponsor: University Hospital, ToursEnrolling: 1004 locations
RECRUITINGNCT06756230

Downhill Walking in IPF

In this study; will examine the effects of downhill walking (eccentric exercise training) on exercise capacity, quality of life, and blood lactate levels in individuals with IPF....

Sponsor: Saglik Bilimleri UniversitesiEnrolling: 341 location
RECRUITINGNCT07083557

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine,...

The purpose of this research study is to validate (check the accuracy of) laboratory assays, intravenous catheter insertion, and equipment or devices and their reproducibility,...

Sponsor: Bettina MittendorferEnrolling: 1001 location
RECRUITINGPhase 1NCT06817590

Nucleoside Therapy in Patients With Telomere Biology Disorders

The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders. The main...

Sponsor: Suneet AgarwalEnrolling: 361 location
RECRUITINGNCT05193136

Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease

We aim to clarify the relationship between sleep hygiene and the onset of sarcopenia or cognitive dysfunction using sleep time, arousal, and sleep quality as indicators in COPD or...

Sponsor: National Hospital Organization Minami Kyoto HospitalEnrolling: 1201 location
RECRUITINGNCT06507956

Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis

Cystic fibrosis is a multisystem genetic disease whose severity, linked to the nature of the mutation in the gene carried, is linked to respiratory impairment, which determines...

Sponsor: Hospices Civils de LyonEnrolling: 2701 location
RECRUITINGNCT06602869

Cellular Markers in Treated or Untreated Non-tuberculous Mycobacterial Respiratory Infection in Patients With Cystic...

This study evaluates a diagnostic serological test for Non-Tuberculous Mycobacteria (NTM) infection in cystic fibrosis patients by measuring T cell response. It aims to highlight...

Sponsor: University Hospital, MontpellierEnrolling: 761 location
RECRUITINGPhase 1NCT07344558

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The...

Sponsor: Mannkind CorporationEnrolling: 249 locations
RECRUITINGNCT06122233

A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease

The goal of this clinical trial is to compare REBUILD-SM (a purpose-built smartphone app and self-management package) with standard care in people with interstitial lung disease...

Sponsor: University of SydneyEnrolling: 4004 locations
RECRUITINGNCT04002882

Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)

Nutrition and body composition, the amount of muscle and fat in the body, has a role in overall health. This study wants to learn more about how nutrition and body composition...

Sponsor: Emory UniversityEnrolling: 902 locations
RECRUITINGPhase 1NCT07407543

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and...

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.

Sponsor: siRNAgen Therapeutics Inc.Enrolling: 301 location
RECRUITINGPhase 1NCT07035990

Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators...

The purpose of Parts D and E of this Phase 1 study are to evaluate the safety, tolerability, and pharmacokinetics of multiple dose combinations of SION-451 and complementary...

Sponsor: Sionna Therapeutics Inc.Enrolling: 1442 locations
RECRUITINGNCT04160715

Korean Idiopathic Pulmonary Fibrosis Registry

This is a multicenter prospective registry of IPF patients in South Korea. The Seoul National University Bundang Hospital is the coordination center for the Korean IPF Registry...

Sponsor: Seoul National University HospitalEnrolling: 30001 location
RECRUITINGNCT04026360

Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease...

This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth...

Sponsor: Insel Gruppe AG, University Hospital BernEnrolling: 5001 location
RECRUITINGNCT07466420

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive...

Sponsor: Katerina M. AntoniouEnrolling: 1001 location
RECRUITINGNCT06599892

CF Organization of Care in the Era of Highly Effective Modulator.

Recently, triple therapy has made it possible to extend access to these modulators to a large proportion of the patient population, with spectacular clinical benefits, provided...

Sponsor: Hospices Civils de LyonEnrolling: 50001 location
RECRUITINGNCT04469439

Impact of Sinus Surgery on Individuals With Cystic Fibrosis

This study will be a prospective, observational study of patients who undergo endoscopic sinus surgery for cystic fibrosis-related chronic rhinosinusitis (CRS). Individuals who do...

Sponsor: University of California, Los AngelesEnrolling: 1709 locations
RECRUITINGNCT06032273

Lung Transplant READY CF 2: CARING CF Ancillary RCT

Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In the United States, more people with CF and low lung function die each year than...

Sponsor: University of WashingtonEnrolling: 1321 location
RECRUITINGNCT01915511

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the...

Sponsor: Duke UniversityEnrolling: 300020 locations
RECRUITINGNCT07508904

Exercises' Effect on Muscle Strength, Aerobic Capacity and Respiratory Functions in Cystic Fibrosis

This research aims to evaluate the effects of upper and lower limb exercises on muscle strength and pulmonary function in children diagnosed with CF. While aerobic training is a...

Sponsor: Riphah International UniversityEnrolling: 221 location
RECRUITINGPhase 2NCT07284459

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in...

Sponsor: Contineum TherapeuticsEnrolling: 32420 locations
RECRUITINGPhase 2NCT06967805

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Sponsor: Mediar TherapeuticsEnrolling: 16420 locations
RECRUITINGNCT04767074

A Non-pharmacological Cough Control Therapy

Coughing affects almost all individuals with ILD leading to physical, psychological and social distress and prevents individuals from performing their activities of daily living,...

Sponsor: West Park Healthcare CentreEnrolling: 242 locations
RECRUITINGNCT05989698

Validation of the C-mo System - Cough Monitoring

The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory...

Sponsor: Cough Monitoring Medical SolutionsEnrolling: 3008 locations
RECRUITINGPhase 3NCT05943535

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

Sponsor: United TherapeuticsEnrolling: 69820 locations
RECRUITINGNCT05818319

Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short...

In cystic fibrosis (CF) renal base excretion is impaired, due to mutations in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene, since CFTR function is crucial in regulation...

Sponsor: University of AarhusEnrolling: 301 location
RECRUITINGNCT03478553

The Genetics of Pulmonary Fibrosis

This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.

Sponsor: University of Colorado, DenverEnrolling: 10001 location
RECRUITINGPhase 2NCT06968845

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a...

Sponsor: Rein TherapeuticsEnrolling: 12019 locations
RECRUITINGPhase 2NCT05975983

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).

Sponsor: InSilico Medicine Hong Kong LimitedEnrolling: 4012 locations
RECRUITINGNCT01851642

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their...

Sponsor: University of FloridaEnrolling: 2201 location
RECRUITINGPhase 2NCT06619561

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be...

Sponsor: Deciphera Pharmaceuticals, LLCEnrolling: 4820 locations
RECRUITINGNCT03120481

Controls for Respiratory Diseases

This is the registry of control participants for patients with various respiratory diseases. We screened healthy volunteers who visited Seoul National Hospital Healthcare System...

Sponsor: Seoul National University HospitalEnrolling: 15721 location
RECRUITINGNCT07289100

Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and...

The goal of this observational study is to learn about new sensors that measure changes in the body that happen during a chest infection, such as breathing rate and heart rate....

Sponsor: Papworth Hospital NHS Foundation TrustEnrolling: 501 location
RECRUITINGEarly Phase 1NCT06267183

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

The purpose of this study is to evaluate safety, tolerability, PK and immunogenicity of SV001 compare to placebo in Chinese healthy adult volunteers.

Sponsor: Shanghai Synvida Biotechnology Co.,Ltd.Enrolling: 531 location
RECRUITINGNCT07255131

The Effectiveness and Efficacy of an Online Cognitive Behavioral Psychotherapeutic Program

An online group cognitive behavioral psychotherapeutic program will be offered to patients with cystic fibrosis and to caregivers by the Hellenic Cystic Fibrosis Association....

Sponsor: Rakitzi, StavroulaEnrolling: 521 location
RECRUITINGPhase 1 / Phase 2NCT03500731

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT,...

Sponsor: Paul SzabolcsEnrolling: 82 locations
RECRUITINGNCT06370962

Circadian Rhythm Disorders in Children With Cystic Fibrosis Under CFTR (Cystic Fibrosis Transmembrane Conductance...

Cystic fibrosis (CF) is a rare disease affecting one out of 4,500 newborns in France (INSERM 2021). Despite major advances in patient care over the past two decades, with...

Sponsor: Hospices Civils de LyonEnrolling: 1803 locations

Showing 50 of 101 trials.Search all Idiopathic Pulmonary Fibrosis trials

Frequently Asked Questions

There are currently 101 clinical trials for Idiopathic Pulmonary Fibrosis, with 101 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Idiopathic Pulmonary Fibrosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 3 Phase 3 trials for Idiopathic Pulmonary Fibrosis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.